论文部分内容阅读
目的:探讨乌苯美司联合紫杉醇与顺铂(TP)方案治疗晚期非小细胞肺癌的临床疗效及对患者免疫功能的影响。方法:选择2013年10月-2015年6月在我院接受治疗的晚期非小细胞肺癌患者60例,随机分为研究组和对照组。两组患者均给予全身化疗治疗,研究组在此基础上给予口服乌苯美司治疗。观察并比较两组患者的临床疗效、免疫功能变化及不良反应的发生情况。结果:研究组患者治疗有效率明显高于对照组,差异具有统计学意义(P<0.05);两组肿瘤控制情况比较,差异无统计学意义(P>0.05);与治疗前比较,两组患者治疗后外周血CD3~+,CD4~+,CD4~+/CD8~+及NK细胞升高,而CD8~+下降,差异具有统计学意义(P<0.05);与对照组比较,研究组患者治疗后外周血CD3~+,CD4~+,CD4~+/CD8~+及NK细胞显著升高,而CD8~+显著降低,差异具有统计学意义(P<0.05);研究组患者白细胞减少、恶心、呕吐及骨髓抑制等不良反应的发生率低于对照组,差异具有统计学意义(P<0.05)。结论:乌苯美司联合TP方案能够改善晚期非小细胞肺癌患者机体免疫功能,减少不良反应的发生率,值得临床推广应用。
Objective: To investigate the clinical efficacy of ubenimex combined with paclitaxel and cisplatin (TP) in the treatment of advanced non-small cell lung cancer and its effect on immune function. Methods: Sixty patients with advanced non-small cell lung cancer treated in our hospital from October 2013 to June 2015 were randomly divided into study group and control group. Two groups of patients were given systemic chemotherapy treatment, the study group on the basis of oral administration of ubenimexes. The clinical efficacy, changes in immune function and incidence of adverse reactions were observed and compared between the two groups. Results: The treatment efficiency in study group was significantly higher than that in control group, the difference was statistically significant (P <0.05). There was no significant difference in tumor control between the two groups (P> 0.05) The levels of CD3 ~ +, CD4 ~ +, CD4 ~ + / CD8 ~ + and NK cells in the peripheral blood of patients after treatment were significantly higher than those in the control group The levels of CD3 ~ +, CD4 ~ +, CD4 ~ + / CD8 ~ + and NK cells in peripheral blood of patients after treatment were significantly increased, while the levels of CD8 ~ + were significantly decreased (P <0.05) , Nausea, vomiting and bone marrow suppression and other adverse reactions than the control group, the difference was statistically significant (P <0.05). Conclusion: Ubenimex combined with TP regimen can improve the immune function and reduce the incidence of adverse reactions in patients with advanced non-small cell lung cancer, which is worthy of clinical application.